Business Information
The group's principal activities are development, production, marketing and distribution of both branded and off-patent pharmaceutical products. The group operates through two business segments: branded and generic pharmaceutical products. Branded pharmaceutical segment includes the lines of women's health, urology/general products and nephrology products. This segment has patent-protected products and trademarked generic products that are promoted directly to healthcare professionals as branded pharmaceutical products. Generic pharmaceutical products segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The group markets their products to pharmaceutical wholesalers, drug distributors and chain drug stores. On 28-Oct-2003, the group acquired amarin development ab.
|
|
Name |
Title
|
Email
|
| Allen Chao | Chmn. | N/A | | Thomas Giordano | CIO, Sr. VP | N/A | | Albert Paonessa | COO, Exec. VP - Anda, Inc, Watson's Distribution Subsidiary | N/A | | Charles Ebert | Sr. VP - Research, Development | N/A | | David Buchen | Sr. VP, General Counsel, Sec. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 1,979,244 | (445,005) | | 2005 | 1,646,203 | 138,233 | | 2004 | 1,640,551 | 151,333
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
